Miebo
ApprovedSmall molecule
Miebo is one of 35 small molecule programs targeting Eye Disease. It is currently in Approved.
2
Indications
5
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
200 competitors in Eye Disease
#DrugCompanyPhaseTrials
1Chantix
PfizerPhase 3
Bayer Aspirin
BayerPhase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
CF101
CCan-Fite BioPharma
Phase 3
Miebo
BBausch & Lomb Incorporated
Approved
Carboxymethylcellulose
AbbViePhase 3
Csa
ZZhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Phase 3
Cenegermin
DDompé Farmaceutici S.p.A
Phase 3
Diquafosol Tetrasodium
Merck & Co.Phase 3
REFRESH LIQUIGEL
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Eye Disease3 trials
Dry Eye1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Miebo. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- BBausch & Lomb Incorporated